Page 890«..1020..889890891892..900910..»

‘It’s all in the brain’: The science behind stuttering – Genetic Literacy Project

Posted: September 22, 2020 at 11:49 pm

Gerald Maguire has stuttered since childhood, but you might not guess it from talking to him. For the past 25 years, Maguire a psychiatrist at the University of California, Riverside has been treating his disorder with antipsychotic medications not officially approved for the condition. Only with careful attention might you discern his occasional stumble on multisyllabic words like statistically and pharmaceutical.

Maguire has plenty of company: More than 70 million people worldwide, including about 3 million Americans, stutter that is, they have difficulty with the starting and timing of speech, resulting in halting and repetition. That number includes approximately 5 percent of children, many of whom outgrow the condition, and 1 percent of adults. Their numbers includepresidential candidate Joe Biden,deep-voiced actor James Earl Jonesand actressEmily Blunt. Though those people and many others, including Maguire, have achieved career success, stuttering can contribute to social anxiety and draw ridicule or discrimination by others.

Maguire has been treating people who stutter, and researching potential treatments, for decades. He receives daily emails from people who want to try medications, join his trials, or even donate their brains to his university when they die. Hes now embarking on a clinical trial of a new medication, called ecopipam, that streamlined speech and improved quality of life in a small pilot study in 2019.

Others, meanwhile, are delving into the root causes of stuttering, which also may point to novel treatments. In past decades, therapists mistakenly attributed stuttering to defects of the tongue and voice box, to anxiety, trauma or even poor parenting and some still do. Yet others have long suspected that neurological problems might underlie stuttering, says J. Scott Yaruss, a speech-language pathologist at Michigan State University in East Lansing. The first data to back up that hunch came in 1991, Yaruss says, when researchers reportedaltered blood flow in the brains of people who stuttered. Over the past two decades, continuing research has made it more apparent that stuttering is all in the brain.

We are in the middle of an absolute explosion of knowledge being developed about stuttering, Yaruss says.

Theres still a lot to figure out, though. Neuroscientists have observed subtle differences in the brains of people who stutter, but they cant be certain if those differences are the cause or a result of the stutter. Geneticists are identifying variations in certain genes that predispose a person to stutter, but the genes themselves are puzzling: Only recently have their links to brain anatomy become apparent.

Maguire, meanwhile, is pursuing treatments based on dopamine, a chemical messenger in the brain that helps to regulate emotions and movement (precise muscle movements, of course, are needed for intelligible speech). Scientists are just beginning to braid these disparate threads together, even as they forge ahead with early testing for treatments based on their discoveries.

Looking at a standard brain scan of someone who stutters, a radiologist wont notice anything amiss. Its only when experts look closely, with specialized technology that shows the brains in-depth structure and activity during speech, that subtle differences between groups who do and dont stutter become apparent.

The problem isnt confined to one part of the brain. Rather, its all about connections between different parts, says speech-language pathologist and neuroscientist Soo-Eun Chang of the University of Michigan in Ann Arbor. For example, in the brains left hemisphere, people who stutter often appear to have slightly weaker connections between the areas responsible for hearing and for the movements that generate speech. Chang has also observed structural differences in the corpus callosum, the big bundle of nerve fibers that links the left and right hemispheres of the brain.

These findings hint that stuttering might result from slight delays in communication between parts of the brain. Speech, Chang suggests, would be particularly susceptible to such delays because it must be coordinated at lightning speed.

Chang has been trying to understand why about 80 percent of kids who stutter grow up to have normal speech patterns, while the other 20 percent continue to stutter into adulthood. Stuttering typically begins when children first start stringing words together into simple sentences, around age 2. Chang studies children for up to four years, starting as early as possible, looking for changing patterns in brain scans.

Its no easy feat to convince such young children to hold still in a giant, thumping, brain-imaging machine. The team has embellished the scanner with decorations that hide all the scary parts. (It looks like an ocean adventure, Chang says.) In kids who lose their stutter, Changs team has observed that the connections between areas involved in hearing and ones involved in speech movements get stronger over time. Butthat doesnt happen in children who continue to stutter.

In another study, Changs group looked at how the different parts of the brain work simultaneously, or dont, using blood flow as a proxy for activity. They found a link between stuttering and a brain circuit called the default mode network, which has roles in ruminating over ones past or future activities, as well as daydreaming. In children who stutter, the default mode network seems to insert itself like a third person butting in on a romantic date intothe conversation between networks responsible for focusing attention and creating movements. That could also slow speech production, she says.

These changes to brain development or structure might be rooted in a persons genes, but an understanding of this part of the problem has also taken time to mature.

In early 2001, geneticist Dennis Drayna received a surprising email: I am from Cameroon, West Africa. My father was a chief. He had three wives and I have 21 full and half siblings. Almost all of us stutter, Drayna recalls it saying. Do you suppose there could be something genetic in my family?

Drayna, who worked at the National Institute on Deafness and Other Communication Disorders, already had a longstanding interest in the inheritance of stuttering. His uncle and elder brother stuttered, and his twin sons did so as children. But he was reluctant to make a transatlantic journey based on an email, and wary that his clinical skills werent up to analyzing the familys symptoms. He mentioned the email to current National Institutes of Health director Francis Collins (director of the National Human Genome Research Institute at that time), who encouraged him to check it out, so he booked a ticket to Africa. He has also traveled to Pakistan, where intermarriage of cousins can reveal gene variants linked to genetic disorders in their children.

Even with those families, finding the genes was slow going: Stuttering isnt inherited in simple patterns like blood types or freckles are. But eventually, Draynas team identified mutations in four genes GNPTAB,GNPTGandNAGPAfrom the Pakistan studies, andAP4E1from the clan in Cameroonthat he estimates may underlie as many as one in five cases of stuttering.

Oddly, none of the genes that Drayna identified have an obvious connection to speech. Rather, they all are involved in sending cellular materials to the waste-recycling compartment called thelysosome. It took more work before Draynas team linked the genes to brain activity.

They started by engineering mice to have one of the mutations theyd observed in people, in the mouse version ofGNPTAB, to see if it affected the mices vocalizations.Mice can be quite chatty, but much of their conversation takes place in an ultrasonic range that people cant hear. Recording the ultrasonic calls of pups, the team observed patterns similar to human stuttering. They have all these gaps and pauses in their train of vocalizations, says Drayna, who cowrote an overview ofgenetics research on speech and language disordersfor theAnnual Review of Genomics and Human Genetics.

Still, the team struggled to spot any clear defect in the animals brains until one determined researcher found that there were fewer of the cells called astrocytes in the corpus callosum. Astrocytesdo big jobs that are essential for nerve activity: providing the nerves with fuel, for example, and collecting wastes. Perhaps, Drayna muses, the limited astrocyte population slows down communication between the brain hemispheres by a tiny bit, only noticeable in speech.

Draynas research has received mixed reviews. Its really been the pioneering work in the field, says Angela Morgan, a speech-language pathologist at the University of Melbourne and Murdoch Childrens Research Institute in Australia. On the other hand, Maguire has long doubted that mutations in such important genes, used in nearly all cells, could cause defects only in the corpus callosum, and only in speech. He also finds it difficult to compare mouse squeaks to human speech. Thats a bit of a stretch, he says.

Scientists are sure there are more stuttering genes to find. Drayna has retired, but Morgan and collaborators areinitiating a large-scale studyin the hopes of identifying additional genetic contributors in more than 10,000 people.

Maguire has been tackling stuttering from a very different angle: investigating the role of dopamine, a key signaling molecule in the brain. Dopamine can ramp up or down the activity of neurons, depending on the brain location and the nerve receptors it sticks to. There are five different dopamine receptors (named D1, D2, and so on) that pick up the signal and respond.

During the 1990s, Maguire and colleagues were among the first to use a certain kind of brain scan, positron emission tomography, on people who stutter. They foundtoomuch dopamine activityin these peoples brains. That extra dopamine seems to stifle the activity of some of the brain regions that Chang and others have linked to stuttering.

Backing up the dopamine connection, other researchers reported in 2009 that people with a certainversion of the D2 receptor gene, one that indirectly enhances dopamine activity, are more likely to stutter.

So Maguire wondered: Could blocking dopamine be the answer? Conveniently, antipsychotic drugs do just that. Over the years, Maguire has conducted small, successful clinical studies with these medications includingrisperidone,olanzapineandlurasidone. (Personally, he prefers the last because it doesnt cause as much weight gain as the others.) The result: Your stuttering wont completely go away, but we can treat it, he says.

None of those medications are approved for stuttering by the US Food and Drug Administration, and they can cause unpleasant side effects, not just weight gain but also muscle stiffness and impaired movement. In part, thats because they act on the D2 version of the dopamine receptor. Maguires new medication, ecopipam, works on the D1 version, which he expects will diminish some side effects though hell have to watch for others, such as weight loss and depression.

In a small study of 10 volunteers, Maguire, Yaruss and colleagues found that people who took ecopipamstuttered lessthan they did pre-treatment. Quality-of-life scores, related to feelings such as helplessness or acceptance of their stutter, also improved for some participants.

Ecopipam isnt the only treatment under consideration. Back in Michigan, Chang hopes thatstimulation of specific parts of the brain during speech could improve fluency. The team uses electrodes on the scalp to gently stimulate a segment of the hearing area, aiming to strengthen connections between that spot and the one that manages speech movements. (This causes a brief tickle sensation before fading, Chang says.) The researchers stimulate the brain while the person undergoes traditional speech therapy, hoping to enhance the therapys effects. Because of the Covid-19 pandemic, the team had to stop the study with 24 subjects out of a planned 50. Theyre analyzing the data now.

Dopamine, cellular waste disposal, neural connectivity how do they fit together? Chang notes that one of the brains circuits involved in stuttering includes two areas that make and use dopamine, which might help explain why dopamine is important in the disorder.

She hopes that neuroimaging can unite the different ideas. As a first stab, she and collaborators compared the problem areas identified by her brain scans tomaps of where various genes are active in the brain. Two of Draynas genes,GNPTGandNAGPA, were active at high levels in the speech and hearing network in the brains of non-stutterers, she saw. That suggests those genes are really needed in those areas, bolstering Draynas hypothesis that defects in the genes would interfere with speech.

The team also observed something novel: Genes involved in energy processing were active in the speech and hearing areas. Theres a big rise in brain activity during the preschool years, when stuttering tends to start, Chang says. Perhaps, she theorizes, those speech-processing regions dont get all the energy they need at a time when they really need to be cranking at maximum power. With that in mind, she plans to look for mutations in those energy-control genes in children who stutter. There are obviously a lot of dots that need to be connected, she says.

Maguire is also connecting dots: He says hes working on a theory to unite his work with Draynas genetic findings. Meanwhile, after struggling through med school interviews and choosing a career in talk therapy despite his difficulties with speech, hes hopeful about ecopipam: With colleagues, hes starting a new study that willcompare 34 people on ecopipam with 34 on placebo. If that treatment ever becomes part of the standard stuttering tool kit, he will have realized a lifelong dream.

Amber Dance is an award-winningfreelance science journalist based in Southern California. She contributes to publications includingPNAS Front Matter,The Scientist, andNature. Find Amber on Twitter @amberldance

A version of this article was originally published at Knowable Magazine and has been republished here with permission. Knowable can be found on Twitter @KnowableMag. Sign up for their newsletter here.

Excerpt from:
'It's all in the brain': The science behind stuttering - Genetic Literacy Project

Posted in Human Genetics | Comments Off on ‘It’s all in the brain’: The science behind stuttering – Genetic Literacy Project

Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the ‘Needle in the Haystack’ Problem of Molecular Biology – Bio-IT World

Posted: September 22, 2020 at 11:49 pm

Patented CRISPRclean Technology is a Foundational Tool that Improves the Performance of Next-Generation Sequencing and Other Molecular Workflows by Increasing Sensitivity, Reducing Costs and Enabling Novel Discovery

CARLSBAD, CA, UNITED STATES - Sep 17, 2020 - Jumpcode Genomics - a genome technology company founded by industry veterans in 2016 focused on improving the understanding of human disease - today exited stealth mode and announced the commercial launch of its CRISPRclean technology. Initially available via three kits, CRISPRclean unlocks the power of next generation sequencing (NGS) by improving sensitivity, reducing costs and simplifying workflows. The company also announced that it has strengthened its leadership team with the addition of Yaron Hakak, Ph.D., as CEO. In addition, the company has added new advisors, including Dr. Stanley Nelson, vice chairman of Human Genetics at UCLA as consulting chief scientist, and Gary Schroth, Ph.D., vice president and distinguished scientist at Illumina, as a member of the companys scientific advisory board.

CRISPRclean technology is based on the in-vitro utilization of the CRISPR/Cas system to cleave and physically remove nucleic acid sequences pre- or post-NGS library preparation. This enables researchers to remove overabundant and uninformative sequences to allow discovery and detection of molecules previously undetectable (the needles). Like polymerase chain reaction (PCR), the technology broadly applies to many molecular biology techniques, particularly sequencing technologies.

Initial research applications focus on ribosomal RNA depletion, single cell analysis and repeat removal for whole genome sequencing. Additionally, Jumpcode Genomics is pursuing clinical applications, including the removal of human host molecules for a universal pathogen test and depletion of wild type alleles for somatic mutation detection in oncology. The technology seamlessly integrates into existing workflows and is agnostic to library preparation methods and sequencing platforms.

We aim to revolutionize the practice of molecular biology with our technology and to drive better results for researchers today and ultimately patients tomorrow, said Dr. Hakak, CEO of Jumpcode Genomics. When researchers perform NGS on biological samples, most molecules sequenced are uninformative, which results in a needle in a haystack problem. CRISPRclean solves this problem by simply removing the haystack.

The expansion of the leadership team and scientific advisory board enables Jumpcode Genomics to commercialize its technology and strengthen direct access to thought leaders in the scientific community.

About Jumpcode Genomics: Founded in 2016, Jumpcode Genomics aims to improve the understanding of human biology and the contribution to disease. The companys proprietary CRISPRclean technology utilizes the CRISPR/Cas system to deplete unwanted nucleic acid molecules from sequencing libraries. The process fits seamlessly within standard next generation sequencing workflows and works with most commercially available library preparation solutions. For more information, please visit: http://www.jumpcodegenomics.com

Original post:
Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the 'Needle in the Haystack' Problem of Molecular Biology - Bio-IT World

Posted in Human Genetics | Comments Off on Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the ‘Needle in the Haystack’ Problem of Molecular Biology – Bio-IT World

Coronavirus mutations: what we’ve learned so far – The Conversation UK

Posted: September 22, 2020 at 11:49 pm

In early January, the first genome sequence of Sars-CoV-2 the virus that causes COVID-19 was released under the moniker Wuhan-1. This string of 30,000 letters (the A, T, C and Gs of the genetic code) marked day one in the race to understand the genetics of this newly discovered coronavirus. Now, a further 100,000 coronavirus genomes sampled from COVID-19 patients in over 100 countries have joined Wuhan-1. Geneticists around the world are mining the data for answers. Where did Sars-CoV-2 come from? When did it start infecting humans? How is the virus mutating and does it matter? Sars-CoV-2 genomics, much like the virus itself, went big and went global.

The term mutation tends to conjure up images of dangerous new viruses with enhanced abilities sweeping across the planet. And while mutations constantly emerge and sometimes sweep early mutations in Sars-CoV-2 have made their way around the world as the virus spread almost unnoticed mutations are a perfectly natural part of any organism, including viruses. The vast majority have no impact on a viruss ability to transmit or cause disease.

A mutation just means a difference; a letter change in the genome. While the Sars-CoV-2 population was genetically essentially invariant when it jumped into its first human host in late 2019, over 13,000 of these changes are now found in the 100,000 Sars-CoV-2 sequenced to date. Yet any two viruses from any two patients anywhere in the world differ on average by only ten letters. This is a tiny fraction of the total 30,000 characters in the viruss genetic code and means that all Sars-CoV-2 in circulation can be considered part of a single clonal lineage.

It will take some time for the virus to acquire substantial genetic diversity. Sars-CoV-2 mutates fairly slowly for a virus, with any lineage acquiring a couple of changes every month; two to six-fold lower than the number of mutations acquired by influenza viruses over the same period.

Still, mutations are the bedrock on which natural selection can act. Most commonly mutations will render a virus non-functional or have no effect whatsoever. Yet the potential for mutations to affect transmissibility of Sars-CoV-2 in its new human hosts exists. As a result, there have been intense efforts to determine which, if any, of the mutations identifiable since the first Sars-CoV-2 genome was sequenced in Wuhan may significantly alter viral function.

An infamous mutation in this context is an amino acid change in the Sars-CoV-2 spike protein, the protein that gives coronaviruses their characteristic crown-like projections and allows it to attach to host cells. This single character change in the viral genome termed D614G has been shown to increase virus infectivity in cells grown in the lab, though with no measurable impact on disease severity. Although this mutation is also near systematically found with three other mutations, and all four are now found in about 80% of sequenced Sars-CoV-2 making it the most frequent set of mutations in circulation.

The challenge with D614G, as with other mutations, is disentangling whether they have risen in frequency because they happened to be present in viruses responsible for seeding early successful outbreaks, or whether they truly confer an advantage to their carriers. While genomics work on a UK dataset suggests a subtle role of D614G in increasing the growth rate of lineages carrying it, our own work could find no measurable impact on transmission.

D614G is not the only mutation found at high frequency. A string of three mutations in the protein shell of Sars-CoV-2 are also increasingly appearing in sequencing data and are now found in a third of viruses. A single change at position 57 of the Orf3a protein, a known immunogenic region, occurs in a quarter. Other mutations exist in the spike protein while myriad others seem induced by the activity of our own immune response. At the same time, there remains no consensus that these, or any others, are significantly changing virus transmissibility or virulence. Most mutations are simply carried along as Sars-CoV-2 continues to successfully spread.

But replacements are not the only small edits that may affect Sars-CoV-2. Deletions in the Sars-CoV-2 accessory genes Orf7b/Orf8 have been shown to reduce the virulence of Sars-CoV-2, potentially eliciting milder infections in patients. A similar deletion may have behaved in the same way in Sars-CoV-1, the related coronavirus responsible for the Sars outbreak in 2002-04. Progression towards a less virulent Sars-CoV-2 would be welcome news, though deletions in Orf8 have been present from the early days of the pandemic and do not seem to be increasing in frequency.

While adaptive changes may yet occur, all the available data at this stage suggests were facing the same virus since the start of the pandemic. Chris Whitty, chief medical officer for England, was right to pour cold water on the idea that the virus has mutated into something milder than the one that caused the UK to impose a lockdown in March. Possible decreases in symptom severity seen over the summer are probably a result of younger people being infected, containment measures (such as social distancing) and improved treatment rather than changes in the virus itself. However, while Sars-CoV-2 has not significantly changed to date, we continue to expand our tools to track and trace its evolution, ready to keep pace.

Go here to see the original:
Coronavirus mutations: what we've learned so far - The Conversation UK

Posted in Human Genetics | Comments Off on Coronavirus mutations: what we’ve learned so far – The Conversation UK

Sex is real – aeon.co

Posted: September 22, 2020 at 11:49 pm

Its uncontroversial among biologists that many species have two, distinct biological sexes. Theyre distinguished by the way that they package their DNA into gametes, the sex cells that merge to make a new organism. Males produce small gametes, and females produce large gametes. Male and female gametes are very different in structure, as well as in size. This is familiar from human sperm and eggs, and the same is true in worms, flies, fish, molluscs, trees, grasses and so forth.

Different species, though, manifest the two sexes in different ways. The nematode worm Caenorhabditis elegans, a common laboratory organism, has two forms not male and female, but male and hermaphrodite. Hermaphroditic individuals are male as larvae, when they make and store sperm. Later they become female, losing the ability to make sperm but acquiring the ability to make eggs, which they can fertilise with the stored sperm.

This biological definition of sex has been swept up into debates over the status of transgender people in society. Some philosophers and gender theorists define a woman as a biologically female human being. Others strongly disagree. Im addressing those who reject the very idea that there are two biological sexes. Instead, they argue, there are many biological sexes, or a continuum of biological sexes.

Theres no need to reject how biologists define the sexes to defend the view that trans women are women. When we look across the diversity of life, sex takes stranger forms than anyone has dreamt of for humans. The biological definition of sex takes all this in its stride. It does so despite the fact that there are no more than two biological sexes in any species youre likely to have heard of. To many people, that might seem to have conservative implications, or to fly in the face of the diversity we see in actual human beings. I will make clear why it does not.

I call this the biological definition of sex because its the one biologists use when studying sex that is, the process by which organisms use their DNA to make offspring. Many philosophers and gender theorists will protest at making the creation of offspring foundational to how we define sex or distinguish different sexes. Theyre surely right that sex as a social phenomenon is much richer than that. But the use of DNA to make offspring is a central topic in biology, and understanding and explaining the diversity of reproductive systems is an important scientific task. Gender theorists are understandably worried about how the biology of sex will be applied or misapplied to humans. What they might not appreciate is why biologists use this definition when classifying the mind-stretching forms of reproduction observed in limpets, worms, fish, lizards, voles and other organisms and they might not understand the difficulties that arise if you try to use another definition.

Many people assume that if there are only two sexes, that means everyone must fall into one of them. But the biological definition of sex doesnt imply that at all. As well as simultaneous hermaphrodites, which are both male and female, sequential hermaphrodites are first one sex and then the other. There are also individual organisms that are neither male nor female. The biological definition of sex is not based on an essential quality that every organism is born with, but on two distinct strategies that organisms use to propagate their genes. They are not born with the ability to use these strategies they acquire that ability as they grow up, a process which produces endless variation between individuals. The biology of sex tries to classify and explain these many systems for combining DNA to make new organisms. That can be done without assigning every individual to a sex, and we will see that trying to do so quickly leads to asking questions that have no biological meaning.

While the biological definition of sex is needed to understand the diversity of life, that doesnt mean its the best definition for ensuring fair competition in sport or adequate access to healthcare. We cant expect sporting codes, medical systems and family law to adopt a definition simply because biologists find it useful. Conversely, most institutional definitions of sex break down immediately in biology, because other species contradict human assumptions about sex. The United States National Institutes of Health (NIH) uses a chromosomal definition of sex XY for males and XX for females. Many reptiles, such as the terrifying saltwater crocodiles of northern Australia, dont have any sex chromosomes, but a male saltie has no trouble telling if the crocodile that has entered his territory is a male. Even among mammals, at least five species are known that dont have male sex chromosomes, but they develop into males just fine. Gender theorists have extensively criticised the chromosomal definition of human sexes. But however well or badly that definition works for humans, its an abject failure when you look at sex across the diversity of life.

The same is true of phenotypic sex, the familiar idea that sex is defined by the typical physical characteristics (phenotypes) of males and females. Obviously, this approach will produce completely different definitions of male and female for humans, for worms, for trees and so forth. Incubating eggs inside your body, for example, is a female characteristic in humans but a male one in seahorses. That doesnt mean that human institutions cant use the phenotypic definition. But it isnt useful when studying the common patterns in the genetics, evolution and so forth of female humans, female seahorses and female worms.

Understanding the complex ways in which chromosomes and phenotypes relate to biological sex will make clear why the biological definition of sex shouldnt be the battleground for philosophers and gender theorists who disagree about the definition of woman. There might be very good reasons not to define woman in this way, but not because the definition itself is poor biology.

Why did sexes evolve in the first place? Biologists define sex as a step towards answering this question. Not all species have biological sexes, and biology seeks to explain why some do and others dont. The fact that no species has evolved more than two biological sexes is also a puzzle. It would be quite straightforward to engineer a species that has three, but none has evolved naturally.

Many species reproduce asexually, with each individual using its own DNA to create offspring. But other species, including our own, combine DNA from more than one organism. Thats sexual reproduction, where two sex cells gametes merge to make a new individual. In some species, these two gametes are identical; many species of yeast, for example, make new individuals from two, identical gametes. They reproduce sexually, but they have no sexes, or, if you prefer, they have only one sex. But in species that make two different kinds of gamete and where one gamete of each kind is needed to make a new organism there are two sexes. Each sex makes one of the two kinds of gamete.

In complex multicellular organisms, such as plants and animals, these two kinds of gamete are very different. One is a large, complex cell, what wed typically call an egg. Its similar to the eggs produced by asexual species, which can develop into a new organism all on their own. Many species of insect and some lizards, snakes and sharks can reproduce using just an egg cell. The other kind of gamete is a much smaller cell that contains very little beyond some DNA and some machinery to get that DNA to the larger gamete. We are familiar with these two kinds of gametes from human eggs and sperm.

Theres no obvious reason why complex multicellular organisms need to have two kinds of gamete, or why these two kinds are so different in size and structure. Its perfectly possible to make three or more different kinds of gamete, or gametes that vary continuously, just as people vary continuously in height. One question that biologists seek to answer, then, is why those forms of sexual reproduction arent observed in complex organisms such as animals and plants.

Earthworms are hermaphrodites: one part of the worm produces sperm and another part produces eggs

When a species produces two different kinds of gamete, biologists call this anisogamy, meaning not-equal-gametes. Some anisogamic species have separate sexes, like humans do, where each individual can produce only one kind of gamete. Other anisogamic species are hermaphrodites, where each individual produces both kinds of gamete. Because they produce two kinds of gametes, hermaphroditic species still have two biological sexes they simply combine them in one organism. When a biologist tells you that earthworms are hermaphrodites, they mean that one part of the worm produces sperm and another part produces eggs.

Some single-celled and very simple multicellular organisms have evolved something called mating types. These are gametes that are identical in size and structure, but in which the genome of each gamete contains genetic markers that affect which other gametes it can combine with. Typically, gametes with the same genetic marker cant recombine with one another. Some species have many hundreds of these mating types, and newspapers often report research into this phenomenon under headlines such as: Scientists discover species with hundreds of sexes! But, formally, biologists refer to these as mating types, and reserve the term sexes for gametes that are different in size and structure.

Why distinguish between these two phenomena? One reason is that the evolution of anisogamy gametes that differ in size and structure explains the later evolution of sex chromosomes, sex-associated physical characteristics and much more. But the existence of mating types doesnt have these dramatic knock-on evolutionary effects. Another reason to keep the distinction is that anisogamy and mating types are thought to have evolved via different evolutionary processes. One theory is that anisogamy appeared when mating-type genome markers somehow became linked to genes that controlled the size of the gamete, or mutated in some way that affected gamete size. These differences in gamete size would then kickstart the evolution of sexes.

The evolution of sex seems to be strongly associated with multicellularity, so the obvious place to look for a shift from mating types to sexes is in organisms that sit at the multicellular boundary such as algae, which sometimes exist as single-celled organisms, and sometimes as colonies of cells. And indeed, there are species of algae where gametes are just a little bit anisogamous, blurring the distinction between mating types and sexes. Theres much we dont know about how sex evolved, and how it might have evolved differently across species. But the point is that sexes and mating types are very different phenomena, with different causes and consequences.

The fact that sex evolved in some species but not others tells us something important about how biologists think about sex. Many cultures take the difference between male and female to be something fundamental, and label other natural phenomena such as the Sun and the Moon as male or female. But for biologists, the separation between male and female is no more fundamental or universal than photosynthesis or being warm-blooded. Some species have evolved these things, and some havent. They exist when they do only because of the local advantages they afforded in evolutionary competition.

So why did some species evolve two, distinct sexes? To answer this question, we need to forget about creatures with complex sex organs and mating behaviours. These evolved later. Instead, think of an organism that releases its gametes into the sea, such as coral, or into the air, such as fungal spores. Next, consider that there are two goals that any gamete must achieve if its to reproduce sexually. The first is finding and recombining with another gamete. The second is producing a new individual with enough resources to survive. One widely accepted idea, then, is that the evolution of sexes reflects a trade-off between these goals. Because no organism has infinite resources, organisms can either produce many small gametes, making it more likely that some of them will find a partner, or produce fewer but larger gametes, making it more likely that the resulting individual will have what it needs to survive and thrive.

Since the 1970s, this idea has been used to model how anisogamic species might have evolved from species with only one kind of gamete. As mutations introduce differences in gamete size, two winning strategies emerge. One is to produce a large number of small gametes too small to create viable offspring unless they recombine with a larger, well-provisioned gamete. The other winning strategy is to produce a few, large, well-resourced gametes that can create viable offspring, no matter how small the recombinant they end up merging with. Intermediate approaches, such as producing a moderate number of moderately well-provisioned gametes, dont do well. Organisms that try to follow the middle way end up with gametes less likely to find a partner than smaller gametes, and more likely to have insufficient resources than larger gametes. When the two successful complementary strategies have evolved, fresh evolutionary pressures make the gametes even more distinct from one another. For example, it can be advantageous for the small gametes to become more mobile, or for the large, immobile gametes to send signals to the mobile ones.

Once anisogamy has evolved, it shapes many other aspects of reproductive biology. Most species of limpet shellfish that you see on rocks at the beach are sequential hermaphrodites. When young and small they are male, and when mature and large they become female. This is believed to be because small limpets dont have sufficient resources to produce large female gametes, but theyre capable of producing the smaller male ones. In some other species, successful males can arrest their growth and remain small (and male) for their entire life.

Chromosomes arent male or female because these bits of DNA define biological sex. Its the other way around

Sequential hermaphroditism occurs in the opposite direction too. Australian snorkellers love to spot the large blue males of the eastern blue groper, but its rare to see more than one. Most groper are smaller, brown females. They are all born female and become sexually mature after a few years, when 20 or 30 cm in length. At around 50 cm, they change sex and acquire other male characteristics, such as being blue. Unlike the limpet, the main problem facing a male groper is controlling a territory on the reef, so becoming male when youre small is a losing strategy.

Biology aims to understand the extraordinary diversity of ways in which organisms reproduce themselves, as well as to identify common patterns, and to explain why they occur. In general, organisms become sexually mature when they reach an optimal size for reproduction. This optimal size is often different for the two sexes, because the two sexes represent divergent strategies for reproduction. The limpet and the groper are two of many examples. In constructing these explanations, biological sex is defined as the production of one type of viable anisogamous gamete. If we defined sex in some other way, it would be hard to see the common patterns across the diversity of life, and hard to explain them.

So-called sex chromosomes, such as the XX and XY chromosome pairs seen in humans, are often brandished as something thats fundamental to sex. Its partly the inadequacy of this definition that drives scepticism about the existence of two, discrete biological sexes. Molecular genetics is likely to require a shift from binary sex to quantum sex, with a dozen or more genes each conferring a small percentage likelihood of male or female sex that is still further dependent on micro- and macroenvironmental interactions, writes the gender scholar Vernon Rosario.

But any biologist already knows that theres more to sex determination than chromosomes and genes, and that male and female sex chromosomes are neither necessary nor sufficient to make organisms male and female. Several species of mammal, all rodents of one kind or another, have completely lost the male Y chromosome, but these rats and voles all produce perfectly normal, fertile males. Other groups of species, such as crocodiles and many fish, have neither sex chromosomes nor any other genes that determine sex. Yet they still have two, discrete biological sexes. The Australian saltwater crocodile, whom we met before, lays eggs that are very likely to develop into gigantic, highly territorial males if incubated between 30 and 33 degrees Celsius. At other temperatures, genetically identical eggs develop into much smaller females.

The reality is that chromosomes arent called male or female because these bits of DNA define biological sex. Its the other way around in some species that reproduce using two discrete sexes, those sexes are associated with different bits of DNA. But in other species this association is either absent or unreliable. Medical institutions use a chromosomal definition of sex because they judge, rightly or wrongly, that this is a reliable way of categorising humans. But humans really arent the best place to start when trying to understand sex across the diversity of life.

So much for genes. But perhaps sex could be defined by the physical characteristics that organisms develop, which then add up to constitute an organisms sex? An organism with more female than male characteristics would be more female than male and vice-versa. Thats a reasonable way to think about sex, and this idea of phenotypic sex is widely used. But if we apply the biological definition of sex, some of the individuals who are in the middle as far as sex-associated characteristics go are bona fide members of one biological sex. Others are not clearly members of either biological sex.

Nothing in the biological definition of sex requires that every organism be a member of one sex or the other. That might seem surprising, but it follows naturally from defining each sex by the ability to do one thing: to make eggs or to make sperm. Some organisms can do both, while some cant do either. Consider the sex-switching species described above: what sex are they when theyre halfway through switching? What sex are they if something goes wrong, perhaps due to hormone-mimicking chemicals from decaying plastic waste? Once we see the development of sex as a process and one that can be disrupted it is inevitable that there will be many individual organisms that arent clearly of either sex. But that doesnt mean that there are many biological sexes, or that biological sex is a continuum. There remain just two, distinct ways in which organisms contribute genetic material to their offspring.

Whats more, the physical characteristics of an organism can be labelled as male or female only if there is already a definition of sex. Whats so male about a groper being blue as opposed to brown? Many male organisms are brown. Whats so female about incubating eggs in a womb? After all, in many pipefish and seahorse species the male incubates the eggs in his brood pouch. What makes this part of the hermaphroditic earthworm male and that part female? Gender studies scholars have noticed this logical discrepancy, and some have gone on to argue that the sexes must therefore be defined in terms of gender. But from a biological perspective, what makes an observable physical characteristic male or female is not its association with gender, but its association with something more tangible: the production of one or other of the two kinds of gamete.

This explains why the existence of individuals with combinations of male and female characteristics doesnt show that biological sex is a continuum. These organisms have a combination of characteristics associated with one biological sex and characteristics associated with the other biological sex. They do not have some part of the ability to make small gametes combined with some part of the ability to make large gametes. Their phenotypic sex might be intermediate, but their biological sex is not. Being fully biologically male and fully biologically female hermaphroditic can be an effective evolutionary strategy, and we have encountered several hermaphroditic species already. But making both kinds of gametes incompletely would be an evolutionary dead-end.

Like phenotypic characteristics, sex chromosomes can be more or less reliably associated with biological sex. The eastern three-lined skink, an Australian lizard, has sex chromosomes, and under some circumstances XY skinks become male and XX skinks become female, just as in humans. But in cold nests, every skink becomes male, whatever their chromosomes. By becomes male, biologists mean that they grow up to produce small gametes sperm.

No animal is conceived with the ability to make sperm or eggs (or both). This ability has to grow

This effect of temperature on sex is not surprising, as many reptile species produce genetically identical offspring whose sex is determined by incubation temperature. Whats more surprising is that varying the size of the egg yolk in this species of skink can produce both sexes with the wrong sex chromosomes: XX males and XY females. The skink seems to have three mechanisms for determining sex chromosomes, temperature and hormones in the yolk. This is not a mere quirk of nature. The skink is one of many species that actively control the sex of their offspring, responding to environmental cues that predict whether male or female offspring have better chances of surviving and reproducing.

If all species were like the skink, we probably wouldnt label sex chromosomes as male or female. After all, we dont think of extreme nest temperatures as female and intermediate temperatures as male, merely because they produce male and female crocodiles or male and female geckos. We think of sex chromosomes as male or female because we focus on species where they are reliably associated with the production of male or female gametes.

Sex chromosomes play much the same role in sex determination as nest temperatures and hormones. Theyre simply mechanisms that organisms use to turn genes on and off in offspring so that they develop a biological sex. No animal is conceived with the ability to make sperm or eggs (or both). This ability has to grow, through a cascade of interactions between genes and environments. In some species, once an individual acquires a sex, it remains that sex for the rest of its life. In others, individuals can switch sex one or more times. But in every case, the underlying mechanisms are designed to grow organisms that make either male or female gametes (or both). The other changes the body undergoes as it becomes male, female or hermaphroditic are designed to fit the reproductive strategies that this species has evolved.

These mechanisms by which organisms develop or switch biological sex are complex, and many factors can interfere with them. So they produce a lot of phenotypic diversity. Sometimes, organisms grow up able to make fertile gametes, but otherwise atypical for their biological sex. Sometimes, they grow up unable to make fertile gametes of either kind. This is usually an accident, but sometimes by design. In bees, eggs that arent fertilised develop into males, so male bees have half as many chromosomes as female bees. Meanwhile, all fertilised eggs start to develop into females, but most of them never complete their sexual development. The queen sends chemical signals that block the development of the worker bees ovaries at an early stage. So worker bees are female in the extended sense that they would develop into fertile females if they werent actively prevented from doing so. Occasionally, worker bees manage to evade these controls and lay their own eggs. They are not popular with beekeepers, who select against these mutant strains.

The diversity of outcomes in individual sexual development doesnt mean that there are many biological sexes or that biological sex is a continuum. Whatever the merits of those views for chromosomal sex or phenotypic sex, they are not true of biological sex. A good way to grasp this is to imagine a species that really does have three biological sexes. Biotechnologists have proposed curing mitochondrial diseases by removing the nucleus from an egg with healthy mitochondrial DNA, and inserting a new nucleus containing the nuclear DNA from an unhealthy egg and the nuclear DNA from a sperm. The resulting child would have three genetic parents.

Now imagine if there was a whole species like this, where three different kinds of gametes combined to make a new individual a sperm, an egg and a third, mitochondrial gamete. This species would have three biological sexes. Something like this has actually been observed in slime moulds, an amoeba that can, but need not, get its mitochondria from a third parent. The novelist Kurt Vonnegut imagined an even more complex system in Slaughterhouse-Five (1969): There were five sexes on Tralfamadore, each of them performing a step necessary in the creation of a new individual. But the first question a biologist would ask is: why havent these organisms been replaced by mutants that dispense with some of the sexes? Having even two sexes imposes many extra costs the simplest is just finding a mate and these costs increase as the number of sexes required for mating rises. Mutants with fewer sexes would leave more offspring and would rapidly replace the existing Tralfamadorians. Something like this likely explains why two-sex systems predominate on Earth.

We can also imagine a species where biological sex really does form a continuum. Recall that some algae have slightly anisogamous gametes, much closer together than sperm and eggs. We can imagine a more complex organism using this system, with some slightly smaller gametes and some slightly larger ones. Successful reproduction might require two gametes that, when added together, are big enough but not too big. But the sexually reproducing plants and animals that actually exist all have just two, very different kinds of gamete male and female. Theyre not merely different in size, theyre fundamentally different in structure. This is the result of competition between organisms to leave the greatest number of genetic descendants. In complex multicellular organisms such as plants and animals, we know of only three successful reproductive strategies: two biological sexes in different individuals, two biological sexes combined in hermaphroditic individuals, and asexual reproduction. Some species use one of these strategies, some use more than one.

Human beings have come up with many ways to classify the diversity of individual outcomes from human sexual development. People who want to apply the biological definition of sex to humans should recognise that its ill-suited to do what many human institutions want, which is to sort every individual into one category or another. What sex are worker bees? They are sterile workers whose genome was designed by natural selection to terminate ovary development on receipt of a signal from the queen bee. They share much of the biology of fertile female bees but if someone wants to know Are worker bees really female?, theyre asking a question that biology simply cant answer.

Nor is being a sterile worker a third biological sex alongside male and female. This is easier to see in ants, where there is more than one sterile caste. Workers, soldiers, queens and male flying ants each have specialised bodies and behaviour, but there are not four biological sexes of ant. Workers and soldiers are both female in an extended sense, but not in the full-blown sense that queen ants are female. There is a human imperative to give everything a sex, as mentioned above, but biology doesnt share it.

The biological definition of sex wasnt designed to ensure fair sporting competition, or settle healthcare disputes

Juvenile organisms and postmenopausal human females also cant produce either kind of gamete. Juveniles are assigned to the sex they have started to grow into. But once again, this is more complicated than it seems when we focus only on humans. In almost all mammals, sexual differentiation is initiated by a region of the Y chromosome, so a mammalian egg can become either male or female. In birds, its the other way around the egg carries the sex-determining W chromosome, so sperm can become either male or female. After fertilisation, therefore, we can say that an individual mammal or bird has a sex in the sense that it has started to grow the ability to produce either male or female gametes. With a crocodile or a turtle, though, wed have to wait until nest temperature had its sex-determining effect. But that doesnt mean that we need to create a third biological sex for crocodile eggs!

More importantly, nothing guarantees that any of these organisms, including those with sex chromosomes, will continue to grow to the point where they can actually produce male or female gametes. Any number of things can interfere. From a biological point of view, there is nothing mysterious about the fact that organisms have to grow into a biological sex, that it takes them a while to get there, and that some individuals develop in unusual or idiosyncratic ways. This is a problem only if a definition of sex must sort every individual organism into one sex or another. Biology doesnt need to do that.

In human populations, there are plenty of individuals whose sex is hard to determine. Biologists arent blind to this. The definition of biological sex is designed to classify the human reproductive system and all the others in a way that helps us to understand and explain the diversity of life. Its not designed to exhaustively classify every human being, or every living thing. Trying to do so quickly leads to questions that have no biological meaning.

Human societies cant delegate to biology the job of defining sex as a social institution. The biological definition of sex wasnt designed to ensure fair sporting competition, or to settle disputes about access to healthcare. Theorists who want to use the biological definition of sex in those ways need to show that it will do a good job at the Olympics or in Medicare. The fact that its needed in biology isnt good enough. On the other hand, whatever its shortcomings as an institutional definition, the concept of biological sex remains essential to understand the diversity of life. It shouldnt be discarded or distorted because of arguments about its use in law, sport or medicine. That would be a tragic mistake.

The authors research is supported by the Australian Research Council and the John Templeton Foundation. He would also like to thank Nicole Vincent, Jussi Lehtonen, Stefan Gawronski and Joshua Christie for their feedback on earlier drafts.

View original post here:
Sex is real - aeon.co

Posted in Human Genetics | Comments Off on Sex is real – aeon.co

Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 billion deal – Metro US

Posted: September 22, 2020 at 11:49 pm

FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California

Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York City

(Reuters) Illumina Inc said on Monday it would buy cancer screening startup Grail Inc in a cash-and-stock deal worth $8 billion, buying out investors including Jeff Bezos and snatching back a business it spun out four years ago.

Grail is developing a liquid biopsy, a blood test intended to diagnose cancers at early stages when the disease is easier to treat. The company has said it expects to launch its flagship test Galleri in 2021, betting on a market expected to grow rapidly in coming years.

Grail was founded by Illumina as a separate company in 2016 and had since raised about $2 billion, with investors including the founders of Amazon.com Inc and Microsoft . Illumina remained its largest shareholder, owning about 14.5% of its outstanding shares. Illumina Chief Executive Francis deSouza said in an interview that he began speaking to his board early this year about acquiring Grail after the start-up released promising data on its experimental diagnostic. From our perspective, early detection of cancer is the largest application of genomics for the next decade, decade and a half, he said. Many cancers, like ovarian cancer, are difficult to diagnose and often only caught when the disease has spread to other areas of the body, when it is far deadlier. If a blood test can effectively detect these cancers earlier, it could significantly improve the prognosis for many patients.

Analysts have forecast a future market for liquid biopsies as high as $130 billion in the United States alone.However, the technology is still experimental and must demonstrate efficacy in clinical trials before being approved by regulators.

Illumina shares fell 8.3% to $271.07, as some analysts questioned the deals rationale.

We dont see the clear fit for acquiring a company that is still at a stage where clinical studies and clinical product development are still critical and will be for years, Cowen analyst Doug Schenkel said in a research note.DeSouza attributed the stock reaction to the deals cost. Its just a big deal. The numbers are large and so investors want to process what this means, he said. DeSouza said the deal fits into Illuminas long-term strategy of developing next generation technology that uses human genetics to improve patients lives.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Bernard Orr and Bill Berkrot)

Read more:
Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 billion deal - Metro US

Posted in Human Genetics | Comments Off on Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 billion deal – Metro US

Global Testosterone Replacement Therapy Market 2020 Trends Analysis and Coronavirus (COVID-19) Effect Analysis | Key Players Market With COVID-19…

Posted: September 21, 2020 at 8:56 pm

Global Testosterone Replacement Therapy Market 2020: Business Growth Rate, Manufacturing Analysis, Size, Share, Cost Structure, and Forecast to 2026

The Market Data Analytics published a recent report on the globalTestosterone Replacement Therapy market, which was studied by the research analysts for months. The report includes information from trusted primary and secondary resources along with detailed examination from the research analysts. Based on the analysis, research analysts have concluded that the global demand for the global Testosterone Replacement Therapy market was USD XX Million in 2019 and is anticipated to reach USD XX Million by the end of 2026. The expected CAGR for the market is around XX%.

Ask for a Sample Copy of the Report (Use Corporate email ID to Get Higher Priority):https://www.marketdataanalytics.biz/global-testosterone-replacement-therapy-market-20202027-by-player-41201.html#request-sample

Final Report will add the analysis of the impact of COVID-19 on this Industry.

The other factors that the report delivers is the revenue estimations, sales volume, industry size, and other important aspects, which includes market segmentation, growth factors, restraints, opportunities, challenges, and the market players.

The global Testosterone Replacement Therapy market incorporates information such as the basic overview of the industry, which includes definition, segmentation, and the industry structure. The global Testosterone Replacement Therapy market is segmented on the basis of{Gels, Injections, Patches, Other}; {Hospitals, Clinics, Others}. Along with this the product types and the applications of the Testosterone Replacement Therapy market are also discussed. Other data that is provided includes developmental trends, regional analysis of the Testosterone Replacement Therapy market, and the technological advancements. The developmental policies that have been updated are all discussed in the report.

Browse Full Report with More Professional and Technical Insights Including COVID-19 Impact@https://www.marketdataanalytics.biz/global-testosterone-replacement-therapy-market-20202027-by-player-41201.html

Some of the top most key players that are enlisted in the report areAbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals. The details that are represented in the report includes the cost structures, manufacturing process methodology, import and export consumption, supply and demand patterns, gross margins, recent developments made in the business, revenue analysis, and gross margins.

The report offers a comprehensive understanding of market dynamics across key regions, namely North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), Latin America (Brazil, Argentina), and the Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa).

Contact Us For More Inquiry of Testosterone Replacement Therapy Report at::https://www.marketdataanalytics.biz/global-testosterone-replacement-therapy-market-20202027-by-player-41201.html#inquiry-for-buying

Key Questions Answered In The Report:

What is the growth potential of the global Testosterone Replacement Therapy market? Which regional market will emerge as a frontrunner during the forecast period 2020-2026? Which application segment will grow at a robust rate? What are the growth opportunities that may emerge in the industry in the years to come? What are the key challenges that the global market may face in the future? Which are the main companies in the global Testosterone Replacement Therapy market? Which are the growth strategies considered by the players to sustain hold in the global market?

Why Go For Market Data Analytics Research?

Market Data Analytics is a leading global market research and consulting firm. We focus on business consulting, industrial chain research, and consumer research to help customers provide non-linear revenue models. We believe that quality is the soul of the business and that is why we always strive for high quality products. Over the years, with our efforts and support from customers, we have collected inventive design methods in various high-quality market research and research teams with extensive experience.

Link:
Global Testosterone Replacement Therapy Market 2020 Trends Analysis and Coronavirus (COVID-19) Effect Analysis | Key Players Market With COVID-19...

Posted in Testosterone Replacement Therapy | Comments Off on Global Testosterone Replacement Therapy Market 2020 Trends Analysis and Coronavirus (COVID-19) Effect Analysis | Key Players Market With COVID-19…

Testosterone Replacement Therapy Market Growth Analysis with Top Players Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International…

Posted: September 21, 2020 at 8:56 pm

GlobalTestosterone Replacement Therapy MarketResearch Report is a resource, which provides current as well as upcoming technical and financial details of the industry to 2027. This report gives you so important and essentials data of Market size, share, trends, Growth, applications, forecast and cost analysis. Delivery development in North America, China, Europe, and South East Asia, Japan as well as in the Globe. The report proves to be indispensable when it comes to market definition, classifications, applications and engagements.

The market report also computes the market size and revenue generated from the sales. The industry analysis report presents the key statistics on the market status of global and regional manufacturers and also acts as a valuable source of leadership and direction. What is more, the Testosterone Replacement Therapy market report analyses and provides historic data along with the current performance of the market.

Get a Free Sample Copy of the Testosterone Replacement Therapy Market Report with Latest Industry Trends @https://www.coherentmarketinsights.com/insight/request-sample/2024

Global Testosterone Replacement Therapy Market competition by Top Key Players: AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.

Testosterone Replacement Therapy Market section by Region:

Segmentation: The report has been separated into different categories, such as product type, application, end user, and region. Every segment is evaluated based on the CAGR, share and growth potential. In the regional analysis, the report highlights the prospective region, which should generate opportunities in the global Testosterone Replacement Therapy market in the years to come. This segmented analysis will surely prove to be a useful tool for readers, stakeholders and market participants to get a full picture of the Testosterone Replacement Therapy global market and its growth potential in the years to come.

The Testosterone Replacement Therapy Market report offers a plethora of insights which include:

Changing consumption patterns among individuals globally.

Historical and future progress of the global Testosterone Replacement Therapy market.

Region-wise and country-wise segmentation of the Testosterone Replacement Therapy market to understand the revenue, and growth lookout in these areas.

Accurate Year-on-Year growth of the global Testosterone Replacement Therapy market.

Important trends, including proprietary technologies, ecological conservation, and globalization affecting the global Testosterone Replacement Therapy market.

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

To get Incredible Discounts on this Premium Report, Click Here @https://www.coherentmarketinsights.com/insight/request-discount/2024

Important Information that can be extracted from the Report:

Assessment of the COVID-19 impact on the growth of the Testosterone Replacement Therapy Market

Successful market entry strategies formulated by emerging market players

Pricing and marketing strategies adopted by established market players

Country-wise assessment of the Testosterone Replacement Therapy Market in key regions

Year-on-Year growth of each market segment over the forecast period 2026

The Testosterone Replacement Therapy Market report considers the following years to predict market growth:

Historic Year: 2014 2018

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2020 2027

The Global Testosterone Replacement Therapy Market is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities

Chapter 2: Market Competition by Manufacturers

Chapter 3: Production by Regions

Chapter 4: Consumption by Regions

Chapter 5: Production, By Types, Revenue and Market share by Types

Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications

Chapter 7: Complete profiling and analysis of Manufacturers

Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Market Effect Factors Analysis

Chapter 12: Market Forecast

Chapter 13: Testosterone Replacement Therapy Research Findings and Conclusion, Appendix, methodology and data source

Have Any Query? Ask Our Expert @ https://www.coherentmarketinsights.com/insight/request-customization/2024

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand].

Contacts Us:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email:[emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

Follow this link:
Testosterone Replacement Therapy Market Growth Analysis with Top Players Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International...

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market Growth Analysis with Top Players Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International…

Testosterone boosters: Uses and effectiveness – Medical News Today

Posted: September 21, 2020 at 8:56 pm

Testosterone boosters include medications and supplements designed to increase testosterone levels in the body. While low testosterone can trigger a range of symptoms, increasing this hormone comes with risks.

In this article, we discuss different types of testosterone boosters and their effectiveness.

Testosterone is an androgen hormone that promotes the development of characteristics people typically associate with masculinity, such as facial hair, deep voice, and muscle growth.

Although testosterone is the principal male sex hormone, it is also present in females, though at much lower levels.

Testosterone influences various aspects of the human body, including:

The normal testosterone value in people varies due to many factors, such as age. The American Urological Association defines low testosterone as less than 300 nanograms per deciliter (ng/dL).

A 2017 study suggests the normal total testosterone range for males aged 1939 years is 264916 ng/dL. The research considers values higher than this as abnormally high.

Low testosterone, or hypogonadism, can occur due to an underlying medical condition, taking certain medications, or injuries to the testes. People may also experience high testosterone levels, typically due to anabolic steroid use, tumors on the adrenal glands, or a medical condition.

A testosterone booster, or testosterone supplement, refers to any natural or artificially produced substance that raises testosterone levels. These may include:

TRT, or androgen replacement therapy, is a medical treatment for low testosterone. It works by replacing the testosterone that the body is not producing. TRT may include:

Injectable testosterone, such as testosterone cypionate (Depo-Testosterone) and testosterone undecanoate (Aveed), contain testosterone esters suspended in oil. Esters are a type of biological compound.

A person can administer this form of testosterone by injecting the solution into the buttocks. People can take these injections every 24 weeks, depending on recommendations from doctors.

Transdermal testosterone includes medicated patches (Androderm) and gels (AndroGel) that people apply directly to the skin.

Androderm patches come in four different strengths: 2 mg, 2.5 mg, 4 mg, or 5 mg of testosterone. The recommended starting dose is one 4 mg patch every 24 hours. A person should apply this to clean, dry skin on the back, thighs, abdomen, or upper arms.

Testosterone gel is available at 1% and 1.62% concentrations. When starting the 1% formulation, a person should apply 50 mg once a day in the morning. The dosage can vary depending on their hormone levels.

Jatenzo is an oral testosterone capsule recently approved by the Food and Drug Administration (FDA) for treating hypogonadism due to underlying medical conditions. The FDA does not recommend Jatenzo for treating age-related low testosterone due to an increased risk of cardiovascular events.

Jatenzo is available in three strengths: 158 mg, 198 mg, and 237 mg. The manufacturers recommend that people start by taking 237 mg twice daily for 1 week. In clinical trials, 87% of participants achieved testosterone levels in the normal range at the end of treatment.

After the first week, a doctor can adjust the dosage according to a persons serum testosterone levels. People should also note that due to a potential increase in blood pressure, Jatenzo may increase the risk of cardiovascular events.

Some supplements may help increase the level of testosterone a persons body produces. These may include:

D-aspartic acid (DAA) is an amino acid that plays a role in creating and releasing several different hormones, including testosterone.

DAA acts on the hypothalamus, triggering an increase of gonadotropin-releasing hormone (GnRH). When GnRH is present, the pituitary gland releases luteinizing hormone (LH), which promotes testosterone production.

Dehydroepiandrosterone (DHEA) is a steroid hormone produced by the adrenal glands. It is a precursor hormone with minimal effects until the body converts it into other hormones, such as estrogen or testosterone.

Due to its effects, DHEA is a popular ingredient in testosterone-boosting supplements.

There are several reasons why a person might use testosterone boosters. These include:

Multiple factors can influence testosterone levels. The body naturally produces less of the hormone with age. In one 2016 study, researchers evaluated the levels of testosterone and DHEA of 271 healthy males between the ages of 4070.

The researchers found testosterone levels decreased by 1.28%, and DHEA decreased by 3.52% each year.

The following factors can lead to low testosterone levels:

TRT is effective in treating low testosterone, but it does not always address the underlying cause. A doctor may recommend lifestyle changes and other medication to treat hypogonadism due to overweight, metabolic disorders, or thyroid problems.

In a 2018 study, researchers coordinated seven controlled trials in 788 older males with low testosterone levels. The participants received either AndroGel 1% or a placebo for 12 months.

The results suggest that testosterone treatment led to moderate improvements in sexual function, bone density, and red blood cell count. Those in the testosterone treatment group showed mild improvements in walking distance, mood, and depressive symptoms.

In a 2017 article, researchers evaluated the efficacy of d-aspartic acid (DAA) reported in 27 animal and human studies.

Findings from the animal studies suggest that DAA increases testosterone levels. However, the human trials produced mixed results. This may be due to limitations of the study design, as well as differences in age, physical fitness levels, and the participants base testosterone levels.

A 2015 study researching the effects of DAA supplementation in 24 males with at least two years of resistance training suggests this technique either showed no significant changes or reduced testosterone levels based on the dosage.

The authors of a 2013 review examined findings from 25 randomized controlled trials that looked at the effects of DHEA supplementation in 1,353 men. The authors conclude it led to minor reductions in body fat, but no improvements in testosterone.

A 2018 review also states there is limited evidence to suggest that DHEA supplementation increases testosterone levels.

Testosterone boosters may provide the following benefits to people with low testosterone levels:

While testosterone replacement may help alleviate the symptoms of hypogonadism, it may not produce the same effects in people with naturally declining testosterone levels.

TRT may lead to the following side effects:

People who inject testosterone may experience pain, swelling, or bruising near the injection site. Topical testosterone gels and patches can also induce allergic reactions at the application site.

The American Urological Association only recommend TRT if a persons testosterone level is below 300 ng/dL, and they show symptoms of hypogonadism. However, the risks of TRT may outweigh its potential benefits.

The FDA does not regulate testosterone supplements, meaning that supplements vary widely in quality, purity, and dosage.

According to the FDA, there is a link between some bodybuilding supplements, as well as products marketed as testosterone alternatives, and the following adverse effects:

Testosterone boosters can help increase a persons testosterone levels. However, their effectiveness will vary based on the type of booster and a persons reasons for taking them.

Testosterone therapy appears to benefit people with conditions such as hypogonadism. However, TRT is usually not recommended to treat age-related declines in testosterone unless managing sexual dysfunction.

More research is necessary to support the use of alternative therapies, such as testosterone supplements. Supplements may also carry some risk of cardiovascular, kidney, and liver disease.

People should always consult a doctor before they start a new medication or supplement.

The rest is here:
Testosterone boosters: Uses and effectiveness - Medical News Today

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone boosters: Uses and effectiveness – Medical News Today

Gene therapy as a potential treatment for glaucoma – AOP

Posted: September 21, 2020 at 8:55 pm

University of Bristol researchers have treated a mouse model of glaucoma using a single gene therapy injection

Pixabay/Arek Socha

Writing in Molecular Therapy, scientists described how CRISPR gene editing was used to inactivate a gene in the ciliary body of the eye, decreasing intraocular pressure.

Visiting senior research fellow at Bristol Medical School, Dr Colin Chu, said the team hoped to advance towards clinical trials of the therapy in the near future.

If it's successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients whilst saving the NHS time and money," Dr Chu said.

Researchers note that while eye drops are currently used to reduce intraocular pressure in glaucoma patients, the drops may have side effects and there are issues of patient compliance in administering the drops daily.

Gene editing to provide a single but permanent therapeutic alteration is an appealing approach given glaucoma is a chronic disease that requires lifelong intervention, the study authors emphasised.

Go here to see the original:
Gene therapy as a potential treatment for glaucoma - AOP

Posted in Gene therapy | Comments Off on Gene therapy as a potential treatment for glaucoma – AOP

University of Edinburgh spinout Cellinta will develop gene therapies for cancer – PharmaTimes

Posted: September 21, 2020 at 8:55 pm

A biotech company spun out of the University of Edinburgh will utilise research to develop new gene therapies to target different types of cancer.

The company, Cellinta Limited, was born out of research from scientists at the University of Edinburgh, and received funding through investments from SV Health Investors and Cancer Research UK.

The funding will be used to develop a pipeline of highly selective gene therapies targeting cancer stem cells in a variety of solid tumour types.

It will draw on research led by Professor Steven Pollard at the University of Edinburgh, which delved into stem cell biology, synthetic biology and cancer genomics.

Cellinta has entered into a collaborative research agreement with the University, and retains the option to license intellectual property developed from research conducted there.

Professor Pollard will join the Cellinta team as scientific founder and a senior adviser, while Dr Soraya Bekkali will take the helm as chief executive officer of the new company.

I am delighted to be leading such an exciting company, said Dr Bekkali.

Cellintas approach offers the opportunity to deliver combinations of therapies selectively to cancer stem cells, bypassing the limitations of traditional treatments which often target single genes or redundant signalling pathways, she added.

Meanwhile, Mike Ross managing partner at London-based SV Health Investors has been appointed chairman of Cellinta.

Cellinta represents a unique opportunity to build a leading company based on exciting and innovative science, with the potential to develop first-in-class therapies, said Ross.

We are delighted with the progress the company has made and extremely pleased to appoint Soraya, who has deep experience in gene therapy across various therapeutic areas, as CEO. We look forward supporting Cellinta in its progress as a pioneer in the field, he added.

Read this article:
University of Edinburgh spinout Cellinta will develop gene therapies for cancer - PharmaTimes

Posted in Gene therapy | Comments Off on University of Edinburgh spinout Cellinta will develop gene therapies for cancer – PharmaTimes

Page 890«..1020..889890891892..900910..»